Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026)
Gilead Sciences' Cash & Equivalents came in at $3.18 billion for Q2 2026, down 38.2% from $5.14 billion a year earlier and down 58.3% from the prior quarter.
Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Gilead Sciences' Cash & Equivalents was $7.56 billion, down 24.3% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of 4.8% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $9.99 billion in FY2024 (+64.2%), $6.09 billion in FY2023 (+12.4%), $5.41 billion in FY2022 (+1.4%) and $5.34 billion in FY2021 (-11.0%).
- The Q2 2026 figure represents the lowest quarterly Cash & Equivalents since Q2 2024.
- Year-over-year, Cash & Equivalents has declined for three consecutive quarters, with growth averaging 23.2% over the last eight quarters.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q2 2025 (growth of 85.6%), and the weakest in Q3 2021 (a decline of 66.1%).
- Business Quant data shows GILD's Cash & Equivalents at $7.63 billion (Q1 2026), $7.56 billion (Q4 2025) and $7.33 billion (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.58 Bn | 1,078.16 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 630.16 Bn | 548.69 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 488.57 Bn | 461.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 359.15 Bn | 313.58 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 274.32 Bn | 238.71 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 246.73 Bn | 220.50 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 224.28 Bn | 179.68 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 187.60 Bn | 161.71 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 161.13 Bn | 108.08 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Vertex Pharmaceuticals | 129.23 Bn | 101.23 Bn | 2.84 Bn | 6.14 Bn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.18 Bn |
| Mar 31, 2026 | 7.63 Bn |
| Dec 31, 2025 | 7.56 Bn |
| Sep 30, 2025 | 7.33 Bn |
| Jun 30, 2025 | 5.14 Bn |
| Mar 31, 2025 | 7.93 Bn |
| Dec 31, 2024 | 9.99 Bn |
| Sep 30, 2024 | 5.04 Bn |
| Jun 30, 2024 | 2.77 Bn |
| Mar 31, 2024 | 4.72 Bn |
| Dec 31, 2023 | 6.09 Bn |
| Sep 30, 2023 | 5.71 Bn |
| Jun 30, 2023 | 5.70 Bn |
| Mar 31, 2023 | 4.94 Bn |
| Dec 31, 2022 | 5.41 Bn |
| Sep 30, 2022 | 4.70 Bn |
| Jun 30, 2022 | 4.74 Bn |
| Mar 31, 2022 | 4.30 Bn |
| Dec 31, 2021 | 5.34 Bn |
| Sep 30, 2021 | 4.36 Bn |
Gilead Sciences Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GILD&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();